Neutrophil-mediated IFN activation in the bone marrow alters b cell development in human and murine systemic lupus erythematosus

Journal of Immunology

Volumn 192, Issue 3, 2014, Pages 906-918

  Palanichamy, Arumugam ^a   Bauer, Jason W ^b   Yalavarthi, Srilakshmi ^c   Meednu, Nida ^a   Barnard, Jennifer ^a   Owen, Teresa ^a   Cistrone, Christopher ^a   Bird, Anna ^a   Rabinovich, Alfred ^a   Nevarez, Sarah ^a   Knight, Jason S ^c   Dedrick, Russell ^d   Rosenberg, Alexander ^a   Wei, Chungwen ^e   Rangel Moreno, Javier ^a   Liesveld, Jane ^a   Sanz, Inaki ^e   Baechler, Emily ^b   Kaplan, Mariana J ^c,f   Anolik, Jennifer H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d XDx Inc   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; INTERFERON;

ADULT; ANIMAL CELL; ARTICLE; BONE MARROW; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NEUTROPHIL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION; REGULATORY MECHANISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; BONE MARROW; CHEMOKINES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPOIESIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MIDDLE AGED; NEUTROPHILS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84893397971     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302112     Document Type: Article

References (71)

1. Crampton, S. P., E. Voynova, and S. Bolland. 2010. Innate pathways to B-cell activation and tolerance. Ann. N. Y. Acad. Sci. 1183: 58-68.
2. Rahman, A., and D. A. Isenberg. 2008. Systemic lupus erythematosus. N. Engl. J. Med. 358: 929-939.
3. Baechler, E. C., P. K. Gregersen, and T. W. Behrens. 2004. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16: 801-807.
4. Ronnblom, L., and V. Pascual. 2008. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17: 394-399.
5. Jego, G., A. K. Palucka, J. P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau. 2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234.
6. Blanco, P., A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-Alpha in systemic lupus erythematosus. Science 294: 1540-1543.
7. Haeryfar, S. M. 2005. The importance of being a pDC in antiviral immunity: the IFN mission versus Ag presentation Trends Immunol. 26: 311-317.
8. Mathian, A., A. Weinberg, M. Gallegos, J. Banchereau, and S. Koutouzov. 2005. IFN-Alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J. Immunol. 174: 2499-2506.
9. Hooks, J. J., H. M. Moutsopoulos, S. A. Geis, N. I. Stahl, J. L. Decker, and A. L. Notkins. 1979. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301: 5-8.
10. Ronnblom, L. E., G. V. Alm, and K. Oberg. 1991. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-Alpha treatment. Acta Oncol. 30: 537-540.
11. Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197: 711-723.
12. Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100: 2610-2615.
13. Knight, J. S., and M. J. Kaplan. 2012. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 24: 441-450.
14. Ahmed, S., and J. H. Anolik. 2010. B-cell biology and related therapies in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 36: 109-130, viii-ix.
15. Arbuckle, M. R., M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. James, and J. B. Harley. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526-1533.
16. Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2: 764-766.
17. Browning, J. L. 2006. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5: 564-576.
18. Anolik, J. H., R. J. Looney, F. E. Lund, T. D. Randall, and I. Sanz. 2009. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol. Res. 45: 144-158.
19. Boulé, M. W., C. Broughton, F. Mackay, S. Akira, A. Marshak-Rothstein, and I. R. Rifkin. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199: 1631-1640.
20. Bave, U., G. V. Alm, and L. Ronnblom. 2000. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-Alpha inducer. J. Immunol. 165: 3519-3526.
21. Bave, U., M. Magnusson, M. L. Eloranta, A. Perers, G. V. Alm, and L. Ronnblom. 2003. Fc gamma RIIa is expressed on natural IFN-Alphaproducing cells (plasmacytoid dendritic cells) and is required for the IFNalpha production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171: 3296-3302.
22. Means, T. K., E. Latz, F. Hayashi, M. R. Murali, D. T. Golenbock, and A. D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115: 407-417.
23. Lin, Q., C. Dong, and M. D. Cooper. 1998. Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 187: 79-87.
24. Lian, Z. X., K. Kikuchi, G. X. Yang, A. A. Ansari, S. Ikehara, and M. E. Gershwin. 2004. Expansion of bone marrow IFN-Alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-Alpha in NZB bone marrow. J. Immunol. 173: 5283-5289.
25. Papadaki, H. A., D. T. Boumpas, F. M. Gibson, D. R. Jayne, J. S. Axford, E. C. Gordon-Smith, J. C. Marsh, and G. D. Eliopoulos. 2001. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br. J. Haematol. 115: 167-174.
26. Touma, Z., M. B. Urowitz, D. Ibanez, and D. D. Gladman. 2011. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 20: 67-70.
27. Bauer, J. W., M. Petri, F. M. Batliwalla, T. Koeuth, J. Wilson, C. Slattery, A. Panoskaltsis-Mortari, P. K. Gregersen, T. W. Behrens, and E. C. Baechler. 2009. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60: 3098-3107.
28. Hu, Y. 2012. Isolation of human and mouse neutrophils ex vivo and in vitro. Methods Mol. Biol. 844: 101-113.
29. Cowand, J. B., and N. Borregaard. 1999. Isolation of neutrophil precursors from bone marrow for biochemical and transcriptional analysis. J. Immunol. Methods 232: 191-200.
30. Denny, M. F., S. Yalavarthi, W. Zhao, S. G. Thacker, M. Anderson, A. R. Sandy, W. J. McCune, and M. J. Kaplan. 2010. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184: 3284-3297.
31. Boxio, R., C. Bossenmeyer-Pourié, N. Steinckwich, C. Dournon, and O. Nusse. 2004. Mouse bone marrow contains large numbers of functionally competent neutrophils. J. Leukoc. Biol. 75: 604-611.
32. Anolik, J. H., J. W. Friedberg, B. Zheng, J. Barnard, T. Owen, E. Cushing, J. Kelly, E. C. Milner, R. I. Fisher, and I. Sanz. 2007. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin. Immunol. 122: 139-145.
33. Anolik, J. H., J. Barnard, A. Cappione, A. E. Pugh-Bernard, R. E. Felgar, R. J. Looney, and I. Sanz. 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50: 3580-3590.
34. Bohnhorst, J. Ø., M. B. Bjørgan, J. E. Thoen, J. B. Natvig, and K. M. Thompson. 2001. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167: 3610-3618.
35. Pascual, V., Y. J. Liu, A. Magalski, O. de Bouteiller, J. Banchereau, and J. D. Capra. 1994. Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med. 180: 329-339.
36. Anolik, J. H., J. Barnard, T. Owen, B. Zheng, S. Kemshetti, R. J. Looney, and I. Sanz. 2007. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56: 3044-3056.
37. Cuss, A. K., D. T. Avery, J. L. Cannons, L. J. Yu, K. E. Nichols, P. J. Shaw, and S. G. Tangye. 2006. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J. Immunol. 176: 1506-1516.
38. Sims, G. P., R. Ettinger, Y. Shirota, C. H. Yarboro, G. G. Illei, and P. E. Lipsky. 2005. Identification and characterization of circulating human transitional B cells. Blood 105: 4390-4398.
39. Bekar, K. W., T. Owen, R. Dunn, T. Ichikawa, W. Wang, R. Wang, J. Barnard, S. Brady, S. Nevarez, B. I. Goldman, et al. 2010. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62: 2443-2457.
40. Aitchison, J. 2001. Simplicial inference. In Algebraic Methods in Statistics and Probability: Contemporary Mathematics Series. A. G. V. Marlos, and D. S. P. Richards, eds. American Mathematical Society, Providence, RI, p. 1-22.
41. Palanichamy, A., J. Barnard, B. Zheng, T. Owen, T. Quach, C. Wei, R. J. Looney, I. Sanz, and J. H. Anolik. 2009. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182: 5982-5993.
42. Merchant, M. S., B. A. Garvy, and R. L. Riley. 1996. Autoantibodies inhibit interleukin-7-mediated proliferation and are associated with the age-dependent loss of pre-B cells in autoimmune New Zealand Black Mice. Blood 87: 3289-3296.
43. Wang, J., Q. Lin, H. Langston, and M. D. Cooper. 1995. Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells. Immunity 3: 475-484.
44. Ryan, D. H., B. L. Nuccie, I. Ritterman, J. L. Liesveld, and C. N. Abboud. 1994. Cytokine regulation of early human lymphopoiesis. J. Immunol. 152: 5250-5258.
45. Garcia-Romo, G. S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, C. Guiducci, R. L. Coffman, et al. 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra20.
46. Lande, R., D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, J. Gregorio, S. Meller, G. Chamilos, R. Sebasigari, V. Riccieri, et al. 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra19.
47. Blomberg, S., M. L. Eloranta, B. Cederblad, K. Nordlin, G. V. Alm, and L. Ronnblom. 2001. Presence of cutaneous interferon-Alpha producing cells in patients with systemic lupus erythematosus. Lupus 10: 484-490.
48. Farkas, L., K. Beiske, F. Lund-Johansen, P. Brandtzaeg, and F. L. Jahnsen. 2001. Plasmacytoid dendritic cells (natural interferon-Alpha/beta- producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159: 237-243.
49. Tucci, M., C. Quatraro, L. Lombardi, C. Pellegrino, F. Dammacco, and F. Silvestris. 2008. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58: 251-262.
50. Kumagai, Y., O. Takeuchi, H. Kato, H. Kumar, K. Matsui, E. Morii, K. Aozasa, T. Kawai, and S. Akira. 2007. Alveolar macrophages are the primary interferonalpha producer in pulmonary infection with RNAviruses. Immunity 27: 240-252.
51. Villanueva, E., S. Yalavarthi, C. C. Berthier, J. B. Hodgin, R. Khandpur, A. M. Lin, C. J. Rubin, W. Zhao, S. H. Olsen, M. Klinker, et al. 2011. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187: 538-552.
52. Nakou, M., N. Knowlton, M. B. Frank, G. Bertsias, J. Osban, C. E. Sandel, H. Papadaki, A. Raptopoulou, P. Sidiropoulos, I. Kritikos, et al. 2008. Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum. 58: 3541-549.
53. Bekeredjian-Ding, I. B., M. Wagner, V. Hornung, T. Giese, M. Schnurr, S. Endres, and G. Hartmann. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. Published erratum appears in 2005 J. Immunol. 174: 5884. J. Immunol. 174: 4043-4050.
54. Uccellini, M. B., L. Busconi, N. M. Green, P. Busto, S. R. Christensen, M. J. Shlomchik, A. Marshak-Rothstein, and G. A. Viglianti. 2008. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-Alpha. J. Immunol. 181: 5875-5884.
55. Gamero, A. M., R. Potla, J. Wegrzyn, M. Szelag, A. E. Edling, K. Shimoda, D. C. Link, J. Dulak, D. P. Baker, Y. Tanabe, et al. 2006. Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J. Biol. Chem. 281: 16238-16244.
56. Ueda, Y., K. Yang, S. J. Foster, M. Kondo, and G. Kelsoe. 2004. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J. Exp. Med. 199: 47-58.
57. Sioud, M., Y. Fløisand, L. Forfang, and F. Lund-Johansen. 2006. Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage. J. Mol. Biol. 364: 945-954.
58. Loder, F., B. Mutschler, R. J. Ray, C. J. Paige, P. Sideras, R. Torres, M. C. Lamers, and R. Carsetti. 1999. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190: 75-89.
59. Carsetti, R., G. Kohler, and M. C. Lamers. 1995. Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181: 2129-2140.
60. Wardemann, H., S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377.
61. Miller, J. P., J. E. Stadanlick, and M. P. Cancro. 2006. Space, selection, and surveillance: setting boundaries with BLyS. J. Immunol. 176: 6405-6410.
62. Sasaki, Y., S. Casola, J. L. Kutok, K. Rajewsky, and M. Schmidt-Supprian. 2004. TNF family member B cell-Activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173: 2245-2252.
63. Batten, M., J. Groom, T. G. Cachero, F. Qian, P. Schneider, J. Tschopp, J. L. Browning, and F. Mackay. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192: 1453-1466.
64. Mackay, F., S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J. L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697-1710.
65. Scapini, P., F. Bazzoni, and M. A. Cassatella. 2008. Regulation of B-cellactivating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol. Lett. 116: 1-6.
66. Huard, B., T. McKee, C. Bosshard, S. Durual, T. Matthes, S. Myit, O. Donze, C. Frossard, C. Chizzolini, C. Favre, et al. 2008. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J. Clin. Invest. 118: 2887-2895.
67. Matthes, T., I. Dunand-Sauthier, M. L. Santiago-Raber, K. H. Krause, O. Donze, J. Passweg, T. McKee, and B. Huard. 2011. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood 118: 1838-1844.
68. Liu, Y. J., C. Barthélémy, O. de Bouteiller, C. Arpin, I. Durand, and J. Banchereau. 1995. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity 2: 239-248.
69. Moser, K., K. Tokoyoda, A. Radbruch, I. MacLennan, and R. A. Manz. 2006. Stromal niches, plasma cell differentiation and survival. Curr. Opin. Immunol. 18: 265-270.
70. Scapini, P., B. Nardelli, G. Nadali, F. Calzetti, G. Pizzolo, C. Montecucco, and M. A. Cassatella. 2003. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med. 197: 297-302.
71. Knight, J. S., W. Zhao, W. Luo, V. Subramanian, A. A. O'Dell, S. Yalavarthi, J. B. Hodgin, D. T. Eitzman, P. R. Thompson, and M. J. Kaplan. 2013. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J. Clin. Invest. 123: 2981-2993.